复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02696 复宏汉霖

休市中 07-03 16:08:15

66.700

-2.000

-2.91%

最高70.650	最低66.500	成交量64.82万
今开69.600	昨收68.700	日振幅6.04%
总市值363.52亿	流通市值232.12亿	总股本5.45亿
成交额4,397万	换手率0.19%	流通股本3.48亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02696","market":"HK","secType":"STK","nameCN":"复宏汉霖","latestPrice":66.7,"timestamp":1783066095007,"preClose":68.7,"halted":0,"volume":648182,"delay":0,"changeRate":-0.02911208151382824,"floatShares":348000000,"shares":545000000,"eps":1.7453422305550106,"marketStatus":"休市中","change":-2,"latestTime":"07-03 16:08:15","open":69.6,"high":70.65,"low":66.5,"amount":43971107,"amplitude":0.060408,"askPrice":66.7,"askSize":2500,"bidPrice":66.6,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":1.7457838791919984,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783301400000},"marketStatusCode":7,"adr":0,"listingDate":1569340800000,"exchange":"SEHK","adjPreClose":68.7,"openAndCloseTimeList":[[1783042200000,1783051200000],[1783054800000,1783065600000]],"volumeRatio":0.40750627024067915,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02696","defaultTab":"news","newsList":[{"id":"2648756745","title":"港股异动 | 复宏汉霖(02696)早盘涨近12% 汉斯状®获英国NICE推荐正式纳入NHS报销体系","url":"https://stock-news.laohu8.com/highlight/detail?id=2648756745","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648756745?lang=zh_cn&edition=full","pubTime":"2026-07-02 11:12","pubTimestamp":1782961934,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖早盘涨近12%，截至发稿，涨7.07%，报68.95港元，成交额5273.15万港元。消息面上，据复宏汉霖官微消息，Accord Healthcare英国与公司近日宣布，H药 汉斯状已获英国国家卫生与临床优化研究所推荐正式纳入英格兰和威尔士国家医疗服务体系常规临床使用范围。随着NICE推荐正式落地及NHS挂网的完成，H药成为首个获得NICE批准、可在英格兰和威尔士用于ES-SCLC治疗的抗PD-1单抗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462167.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000320264.USD","BK4566","IE00BFMHRM44.USD","BK4023","BK4585","HK0000306685.HKD","BK1161","02696","VXUS","HK0000306701.USD","BK4543","NICE","BK4588","HK0000165453.HKD","HK0000320223.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647453054","title":"55家公司港股通新贵即将喜迎北水流入 入通门槛或已抬升至102.67亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2647453054","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647453054?lang=zh_cn&edition=full","pubTime":"2026-07-01 10:09","pubTimestamp":1782871774,"startTime":"0","endTime":"0","summary":"核心规则：市值门槛动态调整截至2026年6月30日，港股通实际纳入门槛已升至102.67亿，剔除门槛达66.89亿。这一指标直接决定了个股在指数中的权重与港股通资格。对于不同上市时长的公司，要求有所不同：对于上市公司而言，维持日均万五左右的换手率是保住港股通资格的关键。数据截止日为每年的6月30日和12月31日，这也是上市公司\"冲关\"港股通的关键时间窗口。","market":"hk","thumbnail":"https://static.tigerbbs.com/0cf777090175126e4590c3b8afdfe41e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/0cf777090175126e4590c3b8afdfe41e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461288.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["01956","00376","02632","01672","03310","02729","03887","01609","07630","02726","01440","00412","02142","03388","02272","02616","01392","02526","06938","00600","01866","02672","07688","06106","09637","07666","02723","01236","03625","01651","01286","06658","02553","00068","02335","03355","06872","00340","00863","01021","02696","01133","06656","01081","06636","01879","09630","06675","03661","02670","01511","BK4585","01779","00100","01191","BK4588","03277"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2647153923","title":"复宏汉霖(02696.HK)：注射用HLX48用于晚期/ 转移性实体瘤治疗的1期临床研究于中国境内完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2647153923","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647153923?lang=zh_cn&edition=full","pubTime":"2026-06-30 17:16","pubTimestamp":1782811018,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HK0000306701.USD","HK0000165453.HKD","BK1161","HK0000306685.HKD","02696","HK0000320264.USD","HK0000320223.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647734737","title":"港股异动 | 复宏汉霖(02696.HK)早盘涨超13% H药在欧盟获批新适应症 实现肺癌核心亚型一线治疗全覆盖","url":"https://stock-news.laohu8.com/highlight/detail?id=2647734737","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647734737?lang=zh_cn&edition=full","pubTime":"2026-06-29 10:36","pubTimestamp":1782700612,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","HK0000306685.HKD","HK0000320264.USD","HK0000165453.HKD","HK0000306701.USD","02696","HK0000320223.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647347370","title":"港股异动 | 复宏汉霖(02696)早盘涨超13% H药在欧盟获批新适应症 实现肺癌核心亚型一线治疗全覆盖","url":"https://stock-news.laohu8.com/highlight/detail?id=2647347370","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647347370?lang=zh_cn&edition=full","pubTime":"2026-06-29 10:36","pubTimestamp":1782700612,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖早盘涨超13%，截至发稿，涨13.33%，报62.9港元，成交额3475.27万港元。这是H药在欧盟获批的第四项适应症，标志着其在欧盟市场实现了对肺癌核心亚型一线治疗的广泛覆盖。作为复宏汉霖全球化战略的核心产品，H药目前已在全球50个国家和地区获批上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1460156.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","HK0000306701.USD","HK0000320223.HKD","BK1161","FESXmain","FSXEmain","BK4585","HK0000165453.HKD","HK0000320264.USD","HK0000306685.HKD","02696","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647545347","title":"复宏汉霖(02696)盘中拉升12.88% 自研HLX13完成美国首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2647545347","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647545347?lang=zh_cn&edition=full","pubTime":"2026-06-29 10:34","pubTimestamp":1782700442,"startTime":"0","endTime":"0","summary":"金吾财讯 | 复宏汉霖 盘中持续拉升，最新报62.65港元，涨幅12.88%，成交额2623.06万港元。消息面上，该公司新近公告称，其自主研发的伊匹木单抗生物类似药HLX13一线治疗不可切除的晚期肝细胞癌患者的国际多中心1期临床研究完成美国首例患者给药。据悉，HLX13拟用于黑色素瘤、肾细胞癌、结直肠癌、肝细胞癌、非小细胞肺癌、恶性胸膜间皮瘤及食管鳞状细胞癌等原研药已获批的适应症。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/MmRhZGRhNjQ0NTZmM2ZiNTY3MTMzODA5NjE3MTg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MmRhZGRhNjQ0NTZmM2ZiNTY3MTMzODA5NjE3MTg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984680","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","HK0000320223.HKD","HK0000320264.USD","HK0000306685.HKD","HK0000306701.USD","02696","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646337092","title":"港股收评：香港恒生指数收跌1.76% “果链”舜宇光学科技跌超9%，鸿腾精密跌近8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646337092","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646337092?lang=zh_cn&edition=full","pubTime":"2026-06-26 16:13","pubTimestamp":1782461622,"startTime":"0","endTime":"0","summary":"6月26日，香港恒生指数收跌1.76%，恒生科技指数收跌3.41%。苹果产业链公司跌幅居前，舜宇光学科技跌超9%，鸿腾精密跌近8%，瑞声科技跌近6%。微观交易层面，三季度港股面临IPO和解禁的流动性供给扰动。相较IPO而言，上市6个月之后的解禁潮对港股市场的负面影响相对更大。","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/06/26161357594543.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["HK0001040143.USD","LU0164880469.USD","LU0149721374.USD","BK1508","BK4502","LU0211977185.USD","BK4577","LU0320764599.SGD","LU0708995153.HKD","LU1102505762.USD","LU0823397103.USD","LU1196710864.SGD","LU0607220059.USD","LU0188438112.USD","HTCD.SI","BK4505","SG9999001051.SGD","HK0000352291.HKD","03690","BK4503","BABO","BK4527","IE00BQXX3F31.USD","LU1951186391.HKD","BK1590","SG9999018857.SGD","LU0106259558.USD","BK4554","BK1506","BABW","LU0878004406.USD","LU0417516571.SGD","SG9999015952.SGD","IE0032431581.USD","SG9999015986.USD","HHImain","LU0831103253.SGD","LU1211504680.USD","LU1770036033.HKD","BK4122","LU0882747503.HKD","82800","IE00B8HQ1Z84.USD","LU0251144936.SGD","LU1196710195.USD","LU1868837722.USD","BK1233","LU1226288097.SGD","BK1610","BK1142","IE00BQXX3D17.EUR","LU0648948544.HKD","LU1642822792.SGD","LU0067412154.USD","LU2039709279.SGD","LU0553294199.USD","SG9999002562.SGD","LU1251922891.USD","LU0541501648.USD","LU1043141396.HKD","LU0455707207.USD","LU0821914370.USD","LU0791591158.USD","BK1618","BK4538","BK4514","LU1804176565.USD","LU2362540622.SGD","BK1608","BK4535","IE00BYV24P56.USD","LU0345775950.USD","LU0608807946.USD","BK4575","LU1224444064.USD","LU0210527791.USD","LU2106854487.HKD","LU0594300179.USD","LU0640798160.USD","LU0862451753.SGD","LU1316542783.SGD","LU0072462343.USD","LU1688375341.USD","LU0192582467.USD","XIACY","SG9999001689.USD","01810","SG9999001093.SGD","LU1691799644.USD","LU1993786604.SGD","BK4504","LU2045819591.USD","LU2476274720.SGD","06088","02837","LU1868837565.USD","LU0797268264.HKD","IE00BVYPNP33.GBP","LU0315179316.USD","LU0229945570.USD","LU0431992006.USD","LU0593848301.USD","IE00BZ08YT58.USD","LU0214875030.USD","06110","IE00B031HY20.USD","BK1521","LU2294711473.HKD","LU0608807433.USD","LU0396098781.USD","LU1228905540.USD","LU0577902538.SGD","IE00B067MR52.USD","01024","09999","LU1366334651.USD","LU2097828714.EUR","LU1044874839.SGD","BK1504","HK0000286598.CNH","HK0000352382.USD","LU2097828474.EUR","LU3227948356.SGD","LU1813983027.USD","LU0293314216.USD","LU0348788117.USD","LU2148611432.USD","LU2778985437.USD","LU1328615791.USD","LU0128525689.USD","BK1193","BK4524","LU0469268626.HKD","LU1794554557.SGD","LU0348805143.USD","LU1568876335.HKD","LU0320764755.SGD","LU0605514214.HKD","LU1785774172.SGD","BK4532","LU0287142896.SGD","LU0819123356.HKD","LU0345776255.USD","LU0417516738.SGD","LU1675838814.USD","LU0650527681.SGD","LU1115378108.SGD","LU1769817096.USD","LU0326950275.SGD","BK1587","LU2488822045.USD","LU0675040207.SGD","HSTECH","SGXZ90724238.SGD","LU0949170772.SGD","LU0348783233.USD","80992","LU0228659784.USD","03037","IE00B97KM107.HKD","LU0128522157.USD","LU0326948709.USD","LU0345769631.USD","LU0823038988.USD","BK4531","BK1170","BK1523","LU0672654166.SGD","LU2362541273.HKD","BK1607","LU0577902454.USD","09067","HK0000914686.HKD","SG9999007991.SGD","LU0084288322.USD","LU0329678337.USD","LU1733274473.HKD","SG9999000327.SGD","SG9999015945.SGD","LU0348723411.USD","LU0594300419.USD","BK4587","LU1655091459.SGD","07226","03423","LU0738912210.USD","LU1629966141.USD","LU0128522744.USD","LU1046421795.USD","LU0264606111.USD","TCEHY","LU0589944569.HKD","LU1152091754.HKD","LU2247934214.USD","HK0000151867.HKD","LU0516423174.USD","LU0516423091.SGD","03067","LU0823426308.USD","SG9999001226.SGD","LU0449509016.USD","IE0031814852.USD","LU1152091168.USD","LU0823413660.USD","LU0196878994.USD","IE00B5MMRT66.SGD","LU1044876610.USD","LU0348784397.USD","LU0577902371.SGD","MCHmain","BK1502","BK4501","LU0320764243.SGD","LU1282651048.USD","ALBmain","SG9999014674.SGD","LU2008162690.USD","LU0203345920.USD","BK1588","BABX","IE0034224299.USD","LU0651946864.USD","LU1725190679.HKD","BK1114","LU0463099449.HKD","BK4534","LU0029875118.USD","IE00BGV7N243.SGD","BK4526","BK1526","LU1366334578.USD","LU0117844026.USD","LU0661504455.SGD","SG9999001903.USD","LU0348825331.USD","LU1046422090.SGD","LU0449515922.USD","LU0348816934.USD","LU0878005551.USD","LU0210526637.USD","002714","LU1226288253.USD","SGXZ51526630.SGD","LU0886674414.USD","METmain","LU1439103000.SGD","LU1481107354.HKD","LU0072913022.USD","LU1807302812.USD","LU0370786039.SGD","BK4579","LU0244354667.USD","LU0642271901.SGD","LU0828238088.HKD","BK4533","BK1615","LU1282651121.HKD","HK0000320264.USD","LU0329678170.USD","LU0426412945.USD","LU0348767384.USD","LU0231483743.USD","LU0499858602.USD","LU0164865239.USD","LU0823039010.USD","LU1831875114.USD","LU0738911758.USD","LU0823426480.USD","LU2237443978.SGD","LU2251237488.HKD","LU1439102457.SGD","LU0823413587.USD","IE00BQXX3C00.GBP","LU0823397285.USD","LU1974910355.USD","03417","09115","LU0048388663.USD","LU0890818403.SGD","LU0307460666.USD","BK4548","LU2097828557.USD","SG9999004220.SGD","LU0096374516.USD","LU0543330566.HKD","LU0348827113.USD","LU0516422366.SGD","SG9999018865.SGD","BK1161","03032","BILI","LU1823568750.SGD","LU2462611646.USD","LU0070217475.USD","LU2237443895.HKD","LNVGY","BABA","LU2125910849.SGD","HK0000306685.HKD","02800","LU1880383440.USD","LU1048596156.SGD","LU0269904917.USD","LU0441854154.USD","LU0588545904.SGD","LU0426417589.USD","LU0572939691.SGD","BK1517","LU0819121731.USD","LU1023057109.AUD","LU1956131251.USD","SG9999001846.SGD","IE00BZ08YR35.GBP","LU0868486357.SGD","LU0531971595.HKD","LU1328277881.USD","BK1224","LU1003077747.HKD","LU0049853897.USD","LU0254981946.USD","LU0011963245.USD","LU1188198961.HKD","LU0856984785.SGD","IE00B031HW06.USD","BK1609","LU0502904849.HKD","LU0700851271.USD","BBYY","LU0228367735.SGD","BK1586","LU1504937902.USD","LU1960683339.HKD","LU0052750758.USD","LU0163747925.USD","LU2148510915.USD","LU1048588211.SGD","LU0047713382.USD","BK1095","LU1303224171.USD","BK4588","LU0140636845.USD","LU0791590937.USD","IE00B0169L03.USD","03033","LU0572944931.SGD","LU0054237671.USD","KBAB","LU0164872284.USD","IE00B0JY6N72.USD","LU0784639295.USD","LU0823040885.USD","01955","BK1516","BK1604","LU1880383366.USD","LU0633140727.USD","LU0456846285.SGD","SG9999017495.SGD","LU0737861772.HKD","LU1224709979.USD","83115","LU2133065610.SGD","BK1589","BK1140","IE0003851619.USD","LU0384037296.USD","LU2449936058.SGD","LU2279701549.SGD","BK1104","HK0000165453.HKD","LU1718418525.SGD","LU1102505929.USD","IE00BVYPNQ40.USD","LU0117841782.USD","SG9999006514.SGD","LU0540923850.HKD","LU0561508036.HKD","LU0043850808.USD","HXXD.SI","81810","NTES","SG9999001069.SGD","IE00BGHQDM52.EUR","IE00B29SXG58.USD","LU0048597586.USD","LU0634319403.HKD","IE0001KFT4U8.USD","LU0588545730.USD","IE0032834883.USD","LU1051769294.HKD","LU2476274308.USD","LU0898667661.SGD","LU0611395673.USD","03088","02833","LU2226246903.HKD","LU1064131003.USD","00992","03419","LU0516422952.EUR","LU0132412106.USD","LU1226287875.USD","LU0315178854.USD","LU1048484197.HKD","LU0683595622.HKD","LU0210533765.USD","LU1267930227.SGD","BK4543","LU0039217434.USD","LU0169518387.USD","LU1917777945.USD","LU1282649141.HKD","LU2237443622.USD","LU0501845795.SGD","LU2317271919.USD","LU0143863784.USD","KSTmain","LU0509642566.USD","LU0972618739.USD","HK0001040168.HKD","LU0289960550.SGD","LU0143863198.USD","LU1568876251.USD","LU0417516902.SGD","LU1226287529.USD","LU0359202008.SGD","BK4607","LU0061477393.USD","LU0080751232.USD","LU0541502299.USD","LU2177674079.SGD","BK4585","SG9999003461.SGD","LU1769817179.HKD","LU2097828805.USD","LU2152927971.USD","LU0049112450.USD","LU0203347892.USD","LU0499858438.USD","LU0871576103.HKD","BK1531","BK4614","JD","07300","LU0051755006.USD","LU1105468828.SGD","MIUmain","LU0516422440.USD","81024","HMTD.SI","LU1196710351.USD","LU0633140560.USD","IE00BMCWC346.EUR","LU0359201612.USD","LU0979878070.USD","LU0414403682.SGD","LU1121112475.USD","LU0456827905.SGD","SG9999006597.SGD","LU1043141123.HKD","LU1868838027.USD","LU2237443465.HKD","LU1282649067.USD","LU2251237306.USD","LU1008478684.HKD","LU0107464264.USD","02382","SG9999014914.USD","LU1961090484.USD","LU1734074674.USD","LU0211331839.USD","HK0000306701.USD","IE0003895053.USD","00700","LU0577902298.EUR","LU2237443382.USD","SG9999002828.SGD","BK1512","BK4509","IE0008368742.USD","LU0348735423.USD","LU0828237940.HKD","LU0261947096.USD","LU0328353924.USD","LU1235294995.USD","LU2265009873.SGD","09626","LU0310800965.SGD","LU1235295612.USD","LU1733274390.USD","LU1770034418.SGD","BK1601","LU0588546209.SGD","SG9999014880.SGD","SG9999015978.USD","BABU","LU0127658192.USD","BK1575","LU0572940350.SGD","HSI","LU0348766576.USD","GB00BDT5M118.USD","LU0873338254.USD","LU0235996351.USD","SGXZ81514606.USD","LU2362541513.USD","SGXZ99366536.SGD","KJD","LU1226288170.HKD","LU2242644610.SGD","IE0009570106.USD","LU2257852520.SGD","LU1044875133.USD","SGXZ31699556.SGD","09088","IE00BZ08YS42.EUR","TCHmain","HK0000320223.HKD","LU1242518857.USD","LU0149534421.HKD","LU0327786744.USD","LU0251143458.SGD","LU0052756011.USD","LU0918141887.USD","BK1602","LU0348814723.USD","IE00B8L5B284.USD","BK1591","LU2023250504.SGD","LU2293587155.HKD","LU0531970944.HKD","LU0708995583.HKD","LU0456842615.SGD","00590","LU0865486749.SGD","LU0545562505.USD","LU0106252389.USD","LU3063872942.SGD","09988","SG9999002463.SGD","IE00B0169N27.USD","LU0918141705.HKD","LU0173614495.USD","LU0994945656.USD","LU2237443549.SGD","MPNGY","BK4551","SG9999000418.SGD","LU0823041008.USD","LU1242518931.SGD","LU0048580855.USD","LU1226287792.SGD","BK4085","BK4220","LU0106959298.USD","LU0345769128.USD","IE0003795394.USD","BK4558","LU1064130708.USD","LU0348783662.USD","HK0000914660.USD","09618","LU1810669033.SGD","SG9999014898.SGD","LU2399975544.HKD","IE00B543WZ88.USD","LU0359201885.HKD","LU1282648689.USD","SG9999014906.USD","LU0259732245.USD","BK4565","BK4581","LU0651947912.USD","LU0737861699.HKD","513600","LU1814569148.SGD","LU0054450605.USD","LU0175139822.USD","IE0008369823.USD","SG9999013353.USD","LU0261950983.USD","LU0880133367.SGD","LU0029874905.USD","LU1228905037.USD","02696","LU1808992512.USD","LU1720050803.USD","LU2498475776.HKD","LU0786609619.USD","IE00BFMHRM44.USD","02714","SG9999000459.SGD","BK1583","LU2097828631.EUR","07552","LU1883866441.USD","LU0545039389.USD","LU1981816686.USD","LU0488056044.USD","LU0314109678.HKD","LU2125910500.SGD","LU2051468812.USD","LU1323998911.USD","LU0181495838.USD","LU1051768304.USD","LU0165289439.USD","LU0588545490.SGD","03115","LU0577902611.USD","IE00B3M56506.USD","IE00BPRC5H50.USD","LU2087589342.USD","LU0543330483.HKD","LU1515016050.SGD","LU1719994722.HKD","LU0828237510.HKD","BK1237","LU0985320562.USD","07500","IE00BF5LJ272.USD","07200","LU0862451837.USD","LU1282649810.SGD","IE0008368411.USD","IE00B031J352.USD","BK1545"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2646871144","title":"复宏汉霖(02696)：伊匹木单抗生物类似药HLX13一线治疗不可切除的晚期肝细胞癌(HCC)患者的国际多中心1期临床研究完成美国首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2646871144","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646871144?lang=zh_cn&edition=full","pubTime":"2026-06-25 18:25","pubTimestamp":1782383143,"startTime":"0","endTime":"0","summary":"HLX13是本公司自主研发的伊匹木单抗生物类似药，拟用于黑色素瘤、肾细胞癌、结直肠癌、肝细胞癌、非小细胞肺癌、恶性胸膜间皮瘤及食管鳞状细胞癌等原研药已获批的适应症。2025年11月，HLX13一线治疗不可切除的肝细胞癌患者的国际多中心1期临床研究于中国境内完成首例患者给药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1458804.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000165453.HKD","02696","HK0000320264.USD","BK1161","BK4006","HK0000320223.HKD","HCC","HK0000306701.USD","HK0000306685.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196520747","title":"复宏汉霖旗下创新药斯鲁利单抗（HETRONIFLY）在欧盟获批鳞状非小细胞肺癌新适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=1196520747","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196520747?lang=zh_cn&edition=full","pubTime":"2026-06-25 18:03","pubTimestamp":1782381795,"startTime":"0","endTime":"0","summary":"上海复宏汉霖生物技术股份有限公司宣布，其创新药物斯鲁利单抗（HETRONIFLY）已获得欧洲委员会批准，新增用于治疗鳞状非小细胞肺癌（SqNSCLC）的适应症。这一重要监管批准标志着该药物在欧盟市场应用范围的进一步扩大，为相关患者群体提供了新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000320264.USD","HK0000320223.HKD","BK1161","HK0000306701.USD","HK0000306685.HKD","HK0000165453.HKD","02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645654978","title":"港股异动 | 复宏汉霖(02696)涨近4% 地舒单抗BILDYOS®与TUZEMTY®在加拿大商业化上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2645654978","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645654978?lang=zh_cn&edition=full","pubTime":"2026-06-24 10:18","pubTimestamp":1782267533,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖涨近4%，截至发稿，涨3.98%，报65.05港元，成交额1050.57万港元。消息面上，6月23日，据复宏汉霖官微消息，公司与Organon加拿大宣布，地舒单抗注射液BILDYOS、地舒单抗注射液TUZEMTY已正式在加拿大实现商业化上市，涵盖原研药PROLIA和XGEVA所有加拿大已获批适应症。据介绍，BILDYOS此次在加拿大上市，进一步丰富了加拿大患者的治疗选择，并通过持续提升生物类似药的可及性帮助降低医疗成本。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457915.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","HK0000306701.USD","BK4585","VXUS","IPOS","HK0000320223.HKD","BK1161","HK0000306685.HKD","HK0000320264.USD","02696","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112474381","title":"Organon加拿大与复宏汉霖推出Prolia与Xgeva生物类似药Bildyos®及Tuzemty®，扩大地舒单抗治疗可及性","url":"https://stock-news.laohu8.com/highlight/detail?id=1112474381","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112474381?lang=zh_cn&edition=full","pubTime":"2026-06-23 17:31","pubTimestamp":1782207107,"startTime":"0","endTime":"0","summary":"Organon加拿大与复宏汉霖通过推出Prolia和Xgeva的生物类似药——Bildyos®（地舒单抗注射液）与Tuzemty®（地舒单抗注射液），显著扩大了地舒单抗治疗的可及性。这两款新药的上市，为患者提供了更多治疗选择，并有望通过竞争促进药品可负担性的提升。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02696","HK0000306685.HKD","HK0000306701.USD","HK0000320223.HKD","HK0000165453.HKD","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644771257","title":"复宏汉霖(02696)：HLX3902注射液用于转移性去势抵抗性前列腺癌及其他晚期实体瘤治疗的1期临床试验申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2644771257","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644771257?lang=zh_cn&edition=full","pubTime":"2026-06-17 17:21","pubTimestamp":1781688115,"startTime":"0","endTime":"0","summary":"HLX3902是公司自主研发的三特异性抗体药物，拟用于治疗转移性去势抵抗性前列腺癌及其他晚期实体瘤。临床前研究显示，HLX3902抗肿瘤疗效及安全性良好，有望获得临床获益。2026年5月，HLX3902用于转移性去势抵抗性前列腺癌及其他晚期实体瘤治疗的1期临床试验已获得相关人类研究伦理委员会的批准，并通过澳大利亚药品管理局 的临床试验备案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000165453.HKD","HK0000320223.HKD","02696","HK0000306701.USD","HK0000306685.HKD","HK0000320264.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644893712","title":"复宏汉霖(02696)：汉倍优(帕妥珠单抗注射液)通过GMP符合性检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2644893712","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644893712?lang=zh_cn&edition=full","pubTime":"2026-06-17 17:14","pubTimestamp":1781687643,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，本公司全资子公司上海复宏汉霖生物医药有限公司收到上海市药品监督管理局颁发的《药品GMP符合性检查告知书》，本公司位于上海市松江区的生物药生产基地顺利通过上海市药品监督管理局针对汉倍优的原液生产东线、制剂生产线及包装线的药品生产质量管理规范符合性检查。2026年5月，汉倍优的上市注册申请获国家药品监督管理局批准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455562.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"复宏汉霖(02696)：汉倍优(帕妥珠单抗注射液)通过GMP符合性检查","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000165453.HKD","HK0000320264.USD","HK0000306685.HKD","BK1161","HK0000320223.HKD","HK0000306701.USD","02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156266712","title":"复宏汉霖宣布HLX04-O治疗湿性年龄相关性黄斑变性三期研究达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1156266712","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156266712?lang=zh_cn&edition=full","pubTime":"2026-06-16 18:47","pubTimestamp":1781606876,"startTime":"0","endTime":"0","summary":"6月16日，上海复宏汉霖生物技术股份有限公司（2696.HK）宣布，其用于治疗湿性年龄相关性黄斑变性（wAMD）的药物HLX04-O，在三期临床研究中已达到预设的主要终点。\n该研究的成功标志着公司在眼科生物类似药领域取得了重要进展。湿性年龄相关性黄斑变性是导致老年人视力丧失的主要原因之一，HLX04-O作为一款创新候选药物，其临床数据备受市场关注。\n公司后续将根据相关法规要求，推进该产品的上市申请工作。此次研究结果的公布，预计将对复宏汉霖的产品管线价值及未来发展产生积极影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02696","HK0000165453.HKD","HK0000320264.USD","HK0000320223.HKD","HK0000306685.HKD","BK1230","HK0000306701.USD","01061","00656"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643300457","title":"复宏汉霖(02696)：注射用HLX43联合汉斯状®用于非小细胞肺癌(NSCLC)新辅助治疗的 2期临床试验于澳大利亚获批开展","url":"https://stock-news.laohu8.com/highlight/detail?id=2643300457","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643300457?lang=zh_cn&edition=full","pubTime":"2026-06-16 17:15","pubTimestamp":1781601353,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖(02696)发布公告，近日，注射用HLX43(靶向PD-L1抗体偶联药物)(HLX43)联合汉斯状®(斯鲁利单抗注射液)(汉斯状®)用于非小细胞肺癌(NSCLC)新辅助治疗的2期临床试验已获得相关人类研究伦理委员会的批准，并通过澳大利亚药品管理局(Therapeutic Goods Administration) 的临床试验备案。本公司拟于条件具备后于澳大利亚开展相关临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454970.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02696","BK1161","HK0000306685.HKD","HK0000165453.HKD","HK0000306701.USD","HK0000320223.HKD","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643073041","title":"复宏汉霖(02696)：重组抗VEGF人源化单克隆抗体注射液HLX04-O用于湿性年龄相关性黄斑变性治疗的国际多中心3期临床研究达到主要研究终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2643073041","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643073041?lang=zh_cn&edition=full","pubTime":"2026-06-16 17:03","pubTimestamp":1781600612,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，重组抗VEGF人源化单克隆抗体注射液HLX04-O在一项于湿性年龄相关性黄斑变性 患者中开展的国际多中心3期临床研究达到主要研究终点。此外，HLX04-O与雷珠单抗在湿性年龄相关性黄斑变性 患者人群中整体、眼部、非眼部的安全性特征均相似，且安全性良好。2025年8月，HLX04-O用于治疗湿性年龄相关性黄斑变性的上市注册申请获国家药品监督管理局药品审评中心受理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454957.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"复宏汉霖(02696)：重组抗VEGF人源化单克隆抗体注射液HLX04-O用于湿性年龄相关性黄斑变性治疗的国际多中心3期临床研究达到主要研究终点","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306701.USD","HK0000320264.USD","BK1161","HK0000320223.HKD","HK0000165453.HKD","HK0000306685.HKD","02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642528692","title":"港股异动 | 复宏汉霖(02696)涨超8% 公司H药汉斯状®斩获全球唯一适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2642528692","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642528692?lang=zh_cn&edition=full","pubTime":"2026-06-12 13:51","pubTimestamp":1781243503,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖涨超8%，截至发稿，涨8.52%，报61.75港元，成交额4221.41万港元。此次获得NMPA批准使得H药成为全球首个且唯一*获批用于胃癌围术期治疗的抗PD-1单抗，填补该领域的临床治疗空白。其商业化价值与未来增长潜力正被重新评估，并有望重塑胃癌治疗格局。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453593.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02696","HK0000306701.USD","BK4588","HK0000320223.HKD","BK1161","HK0000165453.HKD","HK0000306685.HKD","BK4585","VXUS","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642254781","title":"医药板块集体回升 科伦博泰生物(06990)涨7.20%、荣昌生物(09995)涨6.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2642254781","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642254781?lang=zh_cn&edition=full","pubTime":"2026-06-12 13:30","pubTimestamp":1781242214,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医药板块集体回升，科伦博泰生物 涨7.20%，荣昌生物涨6.53%，康诺亚-B涨5.58%，复宏汉霖涨5.36%，康方生物涨5.07%，君实生物涨4.61%，药明合联涨4.06%，诺诚健华涨3.96%。英伟达同时为 Abridge 投资方，新模型基于英伟达开放模型套件 Nemotron 训练，Abridge 将采用去标识化临床数据进行定制优化，预计 2026 年晚些时候上线。东莞证券研报认为，受行业合规整顿以及消费疲软等因素影响，2025年医药生物行业整体归母净利润同比有所下滑。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983673","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","LU2476274308.USD","09939","LU0348825331.USD","09995","BK1587","LU2399975544.HKD","LU0417516902.SGD","LU0348783233.USD","06990","LU0417516738.SGD","LU1720050803.USD","LU0417516571.SGD","LU0561508036.HKD","BK1141","02696","LU0348784397.USD","LU0348827113.USD","HK0000320223.HKD","BK1574","HK0000320264.USD","BK0239","IE00BPRC5H50.USD","BK1161","LU0348766576.USD","01877","LU2328871848.SGD","688331","LU2476274720.SGD","09926","LU0634319403.HKD","159938","LU0540923850.HKD","SG9999014674.SGD","LU1794554557.SGD","02268","LU0348767384.USD","LU1969619763.USD","LU1064130708.USD","02162","LU2148510915.USD","LU0348735423.USD","LU1064131003.USD","LU1961090484.USD","LU2488822045.USD","BK1583","HK0000306701.USD","09969","HK0000165453.HKD","HK0000306685.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132988211","title":"复宏汉霖：发行1,706,750股新股，已发行股本变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1132988211","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132988211?lang=zh_cn&edition=full","pubTime":"2026-06-11 17:37","pubTimestamp":1781170626,"startTime":"0","endTime":"0","summary":"上海复宏汉霖生物技术股份有限公司（股票代码：02696）于2026年6月11日发布翌日披露报表，宣布向公司于2025年7月21日采纳的2025H股受限制股份单位计划之受托人合共配发及发行1,706,750股新股，用于未来归属相关权益。据披露，此次发行股份数量占此前已发行股份总数约0.49%。每股发行价为人民币1元，涉及金额约170.68万元人民币。\n本次发行完成后，公司已发行股本增至347,781,147股，库藏股数保持不变为0股。公司董事会确认，本次股份发行已获得正式授权，并遵守了香港联交所证券上市规则及相关法律法规的要求。公告由董事Wenjie ZHANG签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"复宏汉霖：发行1,706,750股新股，已发行股本变动","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642881072","title":"复宏汉霖(02696)发行合共170.68万股 用于2025年H股受限制股份单位计划归属安排","url":"https://stock-news.laohu8.com/highlight/detail?id=2642881072","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642881072?lang=zh_cn&edition=full","pubTime":"2026-06-11 17:30","pubTimestamp":1781170236,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖(02696)发布公告，公司于2026年6月11日向公司于2025年7月21日采纳的2025H股受限制股份单位计划之受托人配发及发行合共170.68万股新股，以备安排该计划下授予的受限制股份单位的未来归属。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453179.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02696","HK0000306685.HKD","HK0000306701.USD","HK0000320223.HKD","HK0000165453.HKD","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.2018},{"period":"1month","weight":0.1402},{"period":"3month","weight":-0.1292},{"period":"6month","weight":0.1382},{"period":"1year","weight":0.1921},{"period":"ytd","weight":0.1691}],"compareEarnings":[{"period":"1week","weight":0.0299},{"period":"1month","weight":-0.0891},{"period":"3month","weight":-0.0703},{"period":"6month","weight":-0.1135},{"period":"1year","weight":-0.0299},{"period":"ytd","weight":-0.089}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复宏汉霖生物技术股份有限公司是一家主要从事生物制药研发、生物制药服务及生物制药生产与销售的中国公司。该公司的主要产品包括汉曲优（注射用曲妥珠单抗）、汉奈佳（马来酸奈拉替尼片）、汉斯状（斯鲁利单抗注射液）、汉利康（利妥昔单抗注射液）、汉达远（阿达木单抗注射液）、汉贝泰（贝伐珠单抗注射液）等。该公司的产品主要应用于乳腺癌辅助治疗、转移性乳腺癌及转移性胃癌治疗、转移性非鳞状非小细胞肺癌、多关节型幼年特发性关节炎治疗等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.044394},{"month":2,"riseRate":0.714286,"avgChangeRate":0.117695},{"month":3,"riseRate":0.571429,"avgChangeRate":-0.008815},{"month":4,"riseRate":0.857143,"avgChangeRate":0.12138},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.033714},{"month":6,"riseRate":0.571429,"avgChangeRate":0.085211},{"month":7,"riseRate":0.571429,"avgChangeRate":0.064639},{"month":8,"riseRate":0.5,"avgChangeRate":-0.024213},{"month":9,"riseRate":0,"avgChangeRate":-0.127435},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.025526},{"month":11,"riseRate":0.571429,"avgChangeRate":0.058675},{"month":12,"riseRate":0.714286,"avgChangeRate":-0.023816}],"exchange":"SEHK","name":"复宏汉霖","nameEN":"HENLIUS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复宏汉霖,02696,复宏汉霖股票,复宏汉霖股票老虎,复宏汉霖股票老虎国际,复宏汉霖行情,复宏汉霖股票行情,复宏汉霖股价,复宏汉霖股市,复宏汉霖股票价格,复宏汉霖股票交易,复宏汉霖股票购买,复宏汉霖股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}